PKM2 contributes to cancer metabolism

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 184-191

  Wong, Nicholas ^a,b,c,d   Ojo, Diane ^a,b,c,d   Yan, Judy ^a,b,c,d   Tang, Damu ^a,b,c,d  

^a Division of Nephrology   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Aerobic glycolysis; Cancer metabolism; Cell signalling; PKM2

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIMER; MONOMER; MYC PROTEIN; PKM2 PROTEIN; REGULATOR PROTEIN; TETRAMER; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLUCOSE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEMBRANE PROTEIN; MYC PROTEIN, HUMAN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR PROTEIN;

AEROBIC METABOLISM; BIOSYNTHESIS; CANCER METABOLISM; CARCINOGENESIS; CELL METABOLISM; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; METABOLISM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN STABILITY; SHORT SURVEY; TRANSCRIPTION REGULATION; WARBURG EFFECT; CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CARRIER PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; THYROID HORMONES;

EID: 84920201918     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.031     Document Type: Review

References (102)

1. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Stryer L. Glycolysis in Biochemistry 1995, W.H. Freemen and Company, New York, pp. 483-508.
4. Grüning N.M., Rinnerthaler M., Bluemlein K., Mülleder M., Wamelink M.W., Lehrach H., Jakobs C., Breitenbach M., Ralser M. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 2011, 14:415-427.
5. Noguchi T., Yamada K., Inoue H., Matsuda T., Tanaka T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 1987, 262:14366-14371.
6. Noguchi T., Inoue H., Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 1986, 261:13807-13812.
7. Yamada K., Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem. J. 1999, 337(Pt 1):1-11.
8. Imamura K., Tanaka T. Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 1972, 71:1043-1051.
9. Chaneton B., Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 2012, 37:309-316.
10. Muñoz M.E., Ponce E. Pyruvate kinase: current status of regulatory and functional properties. Comp. Biochem. Physiol. B: Biochem. Mol. Biol. 2003, 135:197-218.
11. Bluemlein K., Grüning N.M., Feichtinger R.G., Lehrach H., Kofler B., Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2:393-400.
12. Desai S., Ding M., Wang B., Lu Z., Zhao Q., Shaw K., Yung W.K., Weinstein J.N., Tan M., Yao J. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 2013, [August 7, Epub ahead of print].
13. Mazurek S., Boschek C.B., Hugo F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
14. Saheki S., Harada K., Sanno Y., Tanaka T. Hybrid isozymes of rat pyruvate kinase. Their subunit structure and developmental changes in the liver. Biochim. Biophys. Acta 1978, 526:116-128.
15. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
16. Stuart D.L., Levine M., Muirhead H., Stammers D.K. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. J. Mol. Biol. 1979, 134:109-142.
17. Muirhead H., Clayden D.A., Barford D., Lorimer C.G., Fothergill-Gilmore L.A., Schiltz E., Schmitt W. The structure of cat muscle pyruvate kinase. EMBO J. 1986, 5:475-481.
18. Luo W., Semenza G.L. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011, 2:551-556.
19. Morgan H.P., O'Reilly F.J., Wear W.A., O'Neill J.R., Fothergill-Gilmore L.A., Hupp T., Walkinshaw M.D. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc. Natl. Acad. Sci. USA 2013, 110:5881-5886.
20. Gui D.Y., Lewis C.A., Vander Heiden M.G. Allosteric regulation of PKM2 allows cellular adaptation to different physiological states. Sci. Signal. 2013, 6:pe7.
21. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N., Pandey A., Semenza G.L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
22. Luo W., Semenza G.L. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol. Metab. 2012, 23:560-566.
23. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
24. Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin. Cancer Res. 2012, 18:5546-5553.
25. Garcia-Cao I., Song M.S., Hobbs R.M., Laurent G., Giorgi C., de Boer V.C., Anastasiou D., Ito K., Sasaki A.T., Rameh L., Carracedo A., Vander Heiden M.G., Cantley L.C., Pinton P., Haigis M.C., Pandolfi P.P. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
26. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
27. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 2008, 452:230-233.
28. Brinck U., Eigenbrodt E., Oehmke M., Mazurek S., Fischer G. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 1994, 424:177-185.
29. Schneider J., Neu K., Grimm H., Velcovsky H.G., Weisse G., Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002, 22:311-318.
30. Wechsel H.W., Petri E., Bichler K.H., Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999, 19:2583-2590.
31. Oremek G.M., Teigelkamp S., Kramer W., Eigenbrodt E., Usadel K.H. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res. 1999, 19:2599-2601.
32. Pottek T., Müller M., Blum T., Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res. 2000, 20:5029-5033.
33. Eigenbrodt E., Basenau D., Holthusen S., Mazurek S., Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 1977, 17:3153-3156.
34. Lüftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D., Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res. 2000, 20:5077-5082.
35. Roigas J., Schulze G., Raytarowski S., Jung K., Schnorr D., Loening S.A. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol. 2001, 22:282-285.
36. Hardt P.D., Toepler M., Ngoumou B., Rupp J., Kloer H.U. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res. 2003, 23:851-853.
37. Gordon G.J., Dong L., Yeap B.Y., Richards W.G., Glickman J.N., Edenfield H., Mani M., Colquitt R., Maulik G., Van Oss B., Sugarbaker D.J., Bueno R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl Cancer Inst. 2009, 101:678-686.
38. Lim J.Y., Yoon S.O., Seol S.Y., Hong S.W., Kim J.W., Choi S.H., Cho J.Y. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J. Gastroenterol. 2012, 18:4037-4043.
39. Zhan C., Shi Y., Lu C., Wang Q. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis. Esophagus 2013, 26:746-753.
40. Feng C., Gao Y., Wang C., Yu X., Zhang W., Guan H., Shan Z., Teng W. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2013, 98:E1524-E1533.
41. Karachaliou N., Papadaki C., Lagoudaki E., Trypaki M., Sfakianaki M., Koutsopoulos A., Mavroudis D., Stathopoulos E., Georgoulias V., Souglakos J. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. PLoS ONE 2013, 8:e74611.
42. Li J., Yang Z., Zou Q., Yuan Y., Li J., Liang L., Zeng G., Chen S. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin. Transl. Oncol. 2013, (June 21, Epub ahead of print).
43. Chiavarina B., Whitaker-Menezes D., Martinez-Outschoorn U.E., Witkiewicz A.K., Birbe R., Howell A., Pestell R.G., Smith J., Daniel R., Sotgia F., Lisanti M.P. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 2011, 12:1101-1113.
44. Imamura K., Tanaka T. Pyruvate kinase isozymes from rat. Methods Enzymol. 1982, 90:150-165. Pt E.
45. van Veelen C.W., Staal G.E., Verbiest H., Vlug A.M. Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas?. Lancet 1977, 2:384-385.
46. Vander Heiden M.G., Christofk H.R., Schuman E., et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 2010, 79:1118-1124.
47. Anastasiou D., Yu Y., Israelsen W.J., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 2012, 8:839-847.
48. Kung C., Hixon J., Choe S., et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 2012, 19:1187-1198.
49. Parnell K.M., Foulks J.M., Nix R.N., Clifford A., Bullough J., Luo B., Senina A., Vollmer D., Liu J., McCarthy V., Xu Y., Saunders M., Liu X.H., Pearce S., Wright K., O'Reilly M., McCullar M.V., Ho K.K., Kanner S.B. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 2013, 12:1453-1460.
50. Dombrauckas J.D., Santarsiero B.D., Mesecar A.D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
51. Ashizawa K., McPhie P., Lin K.H., Cheng S.Y. An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1,6-bisphosphate. Biochemistry 1991, 30:7105-7111.
52. Ashizawa K., Willingham M.C., Liang C.M., Cheng S.Y. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 1991, 266:16842-16846.
53. Presek P., Reinacher M., Eigenbrodt E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. Fed. Eur. Biochem. Soc. Lett. 1988, 242:194-198.
54. Hitosugi T., Kang S., Vander Heiden M.G., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:97.
55. McDonnell S.R., Hwang S.R., Rolland D., et al. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. Blood 2013, 122:958-968.
56. Yu Z., Huang L., Zhang T., Yang F., Xie L., Liu J., Song S., Miao P., Zhao L., Zhao X., Huang G. PIM2 phosphorylates PKM2 and promotes Glycolysis in Cancer Cells. J. Biol. Chem. 2013, (October 18, Epub ahead of print, PMID:24142698).
57. Bond C.J., Jurica M.S., Mesecar A., Stoddard B.L. Determinants of allosteric activation of yeast pyruvate kinase and identification of novel effectors using computational screening. Biochemistry 2000, 39:15333-15343.
58. Ikeda Y., Taniguchi N., Noguchi T. Dominant negative role of the glutamic acid residue conserved in the pyruvate kinase M(1) isozyme in the heterotropic allosteric effect involving fructose-1,6-bisphosphate. J. Biol. Chem. 2000, 275:9150-9156.
59. Lv L., Xu Y.P., Zhao D., Li F.L., Wang W., Sasaki N., Jiang Y., Zhou X., Li T.T., Guan K.L., Lei Q.Y., Xiong Y. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 2013, 52:340-352.
60. Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y., Li Z., Xu Y., Wang G., Huang Y., Xiong Y., Guan K.L., Lei Q.Y. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
61. Anastasiou D., Poulogiannis G., Asara J.M., Boxer M.B., Jiang J.K., Shen M., Bellinger G., Sasaki A.T., Locasale J.W., Auld D.S., Thomas C.J., Vander M.G., Heiden L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
62. Ibsen K.H., Marles S.W. Inhibition of chicken pyruvate kinases by amino acids. Biochemistry 1976, 15:1073-1079.
63. Eigenbrodt E., Leib S., Krămer W., Friis R.R., Schoner W. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed. Biochim. Acta 1983, 42:S278-S282.
64. Chaneton B., Hillmann P., Zheng L., Martin A.C., Maddocks O.D., Chokkathukalam A., Coyle J.E., Jankevics A., Holding F.P., Vousden K.H., Frezza C., O'Reilly M., Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012, 491:458-462.
65. Keller K.E., Tan I.S., Lee Y.S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338:1069-1072.
66. Shimada N., Shinagawa T., Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 2008, 13:245-254.
67. Varghese B., Swaminathan G., Plotnikov A., Tzimas C., Yang N., Rui H., Fuchs S.Y. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Mol. Endocrinol. 2010, 24:2356-2365.
68. Kosugi M., Ahmad R., Alam M., Uchida Y., Kufe D. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS ONE 2011, 6:e28234.
69. Mor I., Carlessi R., Ast T., Feinstein E., Kimchi A. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. Oncogene 2012, 31:683-693.
70. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
71. Sun Q., Chen X., Ma J., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 2011, 108:4129-4134.
72. Iqbal M.A., Bamezai R.N. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS ONE 2012, 7:e36764.
73. Ye J., Mancuso A., Tong X., Ward P.S., Fan J., Rabinowitz J.D., Thompson C.B. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. USA 2012, 109:6904-6909.
74. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
75. Liu W., Shen S.M., Zhao X.Y., Chen G.Q. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int. J. Biochem. Mol. Biol. 2012, 3:165-178.
76. 2 tension. Proc. Natl. Acad. Sci. USA 1995, 92:5510-5514.
77. 2 homeostasis. Curr. Opin. Genet. Dev. 1998, 8:588-594.
78. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
79. 2 sensing. Science 2001, 292:464-468.
80. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans; the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
81. Song L.P., Zhang J., Wu S.F., Huang Y., Zhao Q., Cao J.P., Wu Y.L., Wang L.S., Chen G.Q. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2008, 27:519-527.
82. Wenger R.H., Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 1997, 378:609-616.
83. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
84. Meijer T.W., Kaanders J.H., Span P.N., Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin. Cancer Res. 2012, 18:5585-5594.
85. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signalling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 2001, 21:3995-4004.
86. Chen M., Zhang J., Manley J.L. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 2012, 70:8977-8980.
87. Tamada M., Suematsu M., Saya H. Pyruvate kinase m2: multiple faces for conferring benefits on cancer cells. Clin. Cancer Res. 2012, 18(20):5554-5561.
88. Clower C.V., Chatterjee D., Wang Z., Cantley L.C., Vander Heiden M.G., Krainer A.R. The alternative splicing repressors of hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. USA 2010, 107:1894-1899.
89. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
90. Harris I., McCracken S., Mak T.W. PKM2: a gatekeeper between growth and survival. Cell Res. 2012, 22:447-449.
91. Sun Y., Zhao X., Zhou Y., Hu Y. MiR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol. Rep. 2012, 28:1346-1352.
92. Hoshino A., Hirst J.A., Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J. Biol. Chem. 2007, 282:17706-17711.
93. Steták A., Veress R., Ovádi J., Csermely P., Kéri G., Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007, 67:1602-1608.
94. Lee J., Kim H.K., Han Y.M., Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40:1043-1054.
95. Wu S., Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim. Biophys. Sin. (Shanghai) 2013, 45:27-35.
96. Spoden G.A., Morandell D., Ehehalt D., Fiedler M., Jansen-Dürr P., Hermann M., Zwerschke W. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 2009, 107:293-302.
97. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., Lyssiotis C.A., Aldape K., Cantley L.C., Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14:1295-1304.
98. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., Aldape K., Hunter T., Alfred Yung W.K., Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
99. Canal F., Perret C. PKM2: a new player in the β-catenin game. Future Oncol. 2012, 8:395-398.
100. Semenova G., Chernoff J. PKM2 enters the morpheein academy. Mol. Cell 2012, 45:583-584.
101. Cortés-Cros M., Hemmerlin C., Ferretti S., Zhang J., Gounarides J.S., Yin H., Muller A., Haberkorn A., Chene P., Sellers W.R., Hofmann F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl. Acad. Sci. USA 2013, 110:489-494.
102. Israelsen W.J., Dayton T.L., Davidson S.M., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013, 155:397-409.